Loading
Diagnosed with advanced prostate cancer in 1993, the financier founded the Prostate Cancer Foundation, whose grants helped pay for the science behind abiraterone and enzalutamide and built a network of precision oncology centres for US veterans.
Michael Milken, the financier whose junk-bond career ended in a securities-fraud conviction, was diagnosed with advanced prostate cancer in 1993 and, as the Prostate Cancer Foundation's history records, founded the Foundation that year, transforming research, collaboration and awareness. PCF funds investigators and teams rather than running its own laboratories and insists on speed: short applications, fast decisions and a yearly retreat where grantees share unpublished data. Its own history credits $8 million of PCF funding toward the development of abiraterone (Zytiga) and $14.75 million toward enzalutamide (Xtandi), and a $65 million partnership with the US Department of Veterans Affairs in 2016 that established 22 precision oncology centres of excellence. Milken also founded FasterCures, part of the Milken Institute, to speed medical research more broadly.
Shares Funding follows fashion, not burden and the tags hero, donor, patient.
Shares Funding follows fashion, not burden and the tags hero, donor, patient.
Shares Funding follows fashion, not burden and the tags hero, donor, patient.
Shares The valley of death between lab and product, Funding follows fashion, not burden and the tags hero, donor.
Shares David H. Koch, Funding follows fashion, not burden and the tags hero, donor.
Shares Funding follows fashion, not burden, Prostate cancer and the tags hero, donor.
Shares The valley of death between lab and product, Funding follows fashion, not burden and the tags hero, donor.
Shares The valley of death between lab and product, Funding follows fashion, not burden and the tags hero, donor.